Natixis Advisors LLC grew its position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 145.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 360,631 shares of the medical research company's stock after purchasing an additional 213,937 shares during the period. Natixis Advisors LLC owned about 0.24% of Bruker worth $21,140,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. True Wealth Design LLC boosted its stake in Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock worth $36,000 after buying an additional 510 shares in the last quarter. Eagle Bay Advisors LLC boosted its position in Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock valued at $41,000 after buying an additional 674 shares during the period. UMB Bank n.a. grew its stake in shares of Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after buying an additional 248 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Bruker by 47.5% in the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock worth $75,000 after buying an additional 412 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Bruker by 41.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock valued at $78,000 after acquiring an additional 390 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the company. Stifel Nicolaus decreased their price target on Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research note on Friday, February 14th. Barclays dropped their target price on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Bank of America boosted their price target on Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a report on Friday, December 13th. UBS Group started coverage on Bruker in a report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price objective for the company. Finally, The Goldman Sachs Group raised Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price on the stock in a research note on Thursday, December 5th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $70.50.
Read Our Latest Stock Analysis on BRKR
Bruker Stock Down 0.0 %
Shares of BRKR traded down $0.02 during mid-day trading on Friday, reaching $44.45. The company had a trading volume of 2,205,211 shares, compared to its average volume of 1,302,138. Bruker Co. has a 52 week low of $43.10 and a 52 week high of $94.86. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The company has a market capitalization of $6.74 billion, a price-to-earnings ratio of 58.49, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The firm has a 50-day moving average price of $52.49 and a 200 day moving average price of $57.90.
Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, sell-side analysts forecast that Bruker Co. will post 2.69 EPS for the current year.
Bruker Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Monday, March 17th. Bruker's dividend payout ratio (DPR) is currently 26.32%.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Read More
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
